

The Indirect Costs of the SARS-CoV-2 Pandemic: A Case of Severe Malaria in Brooklyn

Eitan Fleischman¹, Akil H. Hutchinson¹, Nawar Z. Paracha¹, Chathula Kumarasinghe¹, Eshan Patel²

1. Internal Medicine, NewYork-Presbyterian Brooklyn Methodist Hospital, Brooklyn, USA 2. Hematology and Oncology, NewYork-Presbyterian Brooklyn Methodist Hospital, Brooklyn, USA

Corresponding author: Akil H. Hutchinson, hasanihutch@gmail.com

Abstract

Severe malaria due to the infection of *Plasmodium falciparum* is a critical infection that may lead to multisystem abnormalities if not promptly and adequately treated. We present a case of severe malaria in a patient recently repatriated from Conakry, Guinea, West Africa, marooned during the recent coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). While the direct costs of the SARS-CoV-2 pandemic and its indirect effect on neighboring industries have been analyzed, the indirect costs of other ailments in medicine have yet to be fully established. This case explores the ramifications of the SARS-CoV-2 pandemic on what would otherwise have been routine prophylaxis of malaria in a traveler. Given the pandemic, the healthcare industry has had fundamental changes that have impacted access to healthcare, particularly in the outpatient setting.

Categories: Internal Medicine, Infectious Disease, Hematology

Keywords: falciparum malaria, severe malaria, sars-cov-2 and covid-19, indirect cost

Introduction

Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), an acute respiratory virus that has caused an unparalleled international health crisis. First noted in China in late December of 2019, the virus has now spread into an international pandemic [1]. Symptomatology ranges from asymptomatic to complex acute respiratory distress requiring mechanical ventilation and prolonged intensive care unit management. At time of publication, the World Health Organization (WHO) reports greater than 36.5 million confirmed cases and over 837 thousand associated deaths [2].

Due to rampant spread, high transmission rates, and acuity, COVID-19 has caused an unprecedented upset in numerous economic, educational, and medical sectors [3]. In healthcare, the medical provider's focus has been shifted from routine follow-up, treatment, and health maintenance to COVID-19 prevention and treatment. From a patient perspective, fear of contraction, insurance loss, and reduced accessibility to medical care have inhibited patients from interfacing with the healthcare system. The lack of routine healthcare had led to a yet uncalculated indirect cost of the COVID-19 pandemic. We describe an unusual case of severe malaria in Brooklyn; a small microcosm of the indirect costs of the current COVID-19 pandemic.

Case Presentation

A 26-year-old male with no known past medical history presented with recurrent fevers, nausea, vomiting, myalgias, and decreased oral intake. He was recently repatriated from Conakry, Guinea after a three-month travel ban during the SARS-CoV-2 pandemic. Initial itinerary was for a two-week excursion and adequate malaria prophylaxis was obtained. Upon return, he delayed his presentation to the ED for five days due to fears of contracting SARS-CoV-2. On presentation the patient was found to be febrile to 39.4°C. His blood smear was positive for *Plasmodium falciparum* with 14% infected red blood cells, thrombocytopenia of 25 K/uL, lactate dehydrogenase of 874 u/L and haptoglobin <31 mg/dL. He was started on a combination atovaquone and proguanil regimen and parasitology was monitored daily for decrease in infection rate.

Fevers and vomiting persisted throughout the beginning of his hospitalization. Repeat parasitology showed a decrease in infected cells to 7%. Thrombocytopenia improved (39 K/uL), however the patient became anemic (hemoglobin (Hgb) 15.1 g/dL to 11.4 g/dL) from admission. On day three there was concern for decreased bioavailability of treatment due to persistent emesis. Repeat parasitology showed a decrease of infected cells to 0.2%. The patient was continued on treatment for an additional day due to partial emesis on day two. On day four, parasitology showed 0.0% infected cells, and no blood parasites were observed. His symptoms resolved completely. The patient was subsequently discharged from the hospital without further complications and scheduled for outpatient follow-up.

Discussion

How to cite this article

Fleischman E, Hutchinson A H, Paracha N Z, et al. (December 27, 2020) The Indirect Costs of the SARS-CoV-2 Pandemic: A Case of Severe Malaria in Brooklyn. Cureus 12(12): e12331. DOI 10.7759/cureus.12331

Review began 12/13/2020

Review ended 12/23/2020

Published 12/27/2020

© Copyright 2020

Fleischman et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

In 1990 (with subsequent revisions in 2000), the WHO defined criteria for severe malaria as *Plasmodium falciparum*-infected erythrocytes percentage greater than 5%, severe anemia due to hemolysis, hemoglobinuria, cerebral malaria, acute kidney injury, acute respiratory distress syndrome (ARDS), pulmonary edema, jaundice, bleeding, hypotension, metabolic acidosis, and hypoglycemia [4]. The incubation time for *P. falciparum* malaria can vary between 12-14 days but may involve longer periods with inadequate prophylaxis. It is more often seen in industrialized countries as travelers from non-endemic countries returning from their travels [5].

When inadequate prophylaxis or resistance to prophylactic medications occurs, treatment is time-dependent and determines the severity of complications. Treatment of malaria depends on multiple factors which include the patient's age and their degree of background immunity, the severity of infection, and susceptibility to antimalarial medications along with the cost and availability of these medications. In particular, the choice of treatment for *P. falciparum* depends on the sensitivity of the parasite to antimalarial medications in the place it was acquired. Infections acquired from North Africa, Middle East, Haiti, and Central America north of the Panama Canal are treated with chloroquine which is a three-day course of 25 mg/kg divided into three daily doses of 10 mg/kg for the first two days and 5 mg/kg on the third day. Amodiaquine is a more effective alternative in areas where there is a low resistance to chloroquine and is given as 35 mg/kg over three days [6]. Infections from chloroquine-resistant areas, like some regions of Asia and South America, are treated with a single-dose combination of pyrimethamine and a long-acting sulfonamide (most commonly sulfadoxine) [6]. Unfortunately, resistance to this combination has developed in Southeast Asia and South America [4]. The choice of treatment for multi-drug resistant *P. falciparum* is mefloquine, halofantrine, or quinine with tetracycline [6]. Artesunate, another restricted antimalarial which may be used for severe malaria treatment (2.4 mg/kg IV q12h x three doses, then 2.4 mg/kg for up to seven days) and distributed by the Centers for Disease Control and Prevention (CDC) in the US. Studies have shown that there is an increase in parasite clearance compared to quinine-based drugs [7]. The patient in this report was treated with Malarone for a total of four days but was evaluated for artesunate due to concerns of non-responsive parasitology despite treatment. Ultimately artesunate was not administered as red blood cell (RBC) involvement dropped from 7% to 0.2% following Malarone use. While treatment of malaria can be fairly uncomplicated, it is highly dependent on the availability of medications and acuity of care. The patient did not receive adequate prophylaxis and fear of SARS-CoV-2 led secondarily to an unanticipated cost of the current pandemic

The direct costs of the SARS-CoV-2 pandemic have been thoroughly studied, but indirect costs are far more insidious. The direct median costs for hospitalizations of acute COVID-19 infection in the US have been estimated to be \$3,045 per person [3]. A proposed attack rate of 20% would account for greater than \$163 billion over the acute infectious phase of the virus. Estimates of this magnitude assess the direct acute costs of COVID-19 and do not account for rehabilitation and recovery. The indirect costs of untreated comorbidities, undiagnosed illness, and lack of preventive care for the rest of the healthcare sector have yet to be fully studied.

Indirect costs are the measure of expense not directly attributable to the original cost. It is often an unforeseen trickle-down pertaining to the inciting event that does not become readily apparent until later. It may be calculated as not only a financial burden, but the emotional and social costs to the patient and caregivers as well. The indirect costs of COVID-19 are being studied in sectors such as education, finance, and agriculture; however, little is yet known about the indirect healthcare costs associated with the COVID-19 pandemic [8,9]. Amimo et al. propose a potential increase and severity of endemic HIV, malaria, and tuberculosis in Africa secondary to COVID-19 and lack of treatment on current endemic ailments [10]. Chronic medical conditions such as congestive heart failure and obesity, already large burdens on the US healthcare system, may not have been effectively treated, and the lapse of care during this time would only propel these comorbid costs [3,11].

Conclusions

The lack of proper personal protective equipment, fear of contraction, reduced transportation, and abbreviated outpatient medicine has led to a yet unmeasured decrease in management of acute and chronic disease in both the outpatient and inpatient settings. Patients such as the one described in this article have had their access to routine healthcare abruptly stopped due to COVID-19. It is therefore incumbent to consider not only the direct costs of the recent pandemic but attempt to anticipate the indirect ramifications as well.

Additional Information

Disclosures

Human subjects: Consent was obtained by all participants in this study. New York Methodist Hospital IRB issued approval 1643377-1. Please note that New York Methodist Hospital IRB has taken the following action on IRBNet: Project Title: [1643377-1] Indirect cost of COVID19: A Case of Severe Malaria in Brooklyn Principal Investigator: Eshan Patel, MD Submission Type: New Project Date Submitted: August 9, 2020 Action: EXEMPT Effective Date: August 18, 2020 Review Type: Expedited Review . **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services**

info: All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Lu H, Stratton CW, Tang YW: Outbreak of pneumonia of unknown etiology in Wuhan, China: the mystery and the miracle. *J Med Virol*. 2020, 92:401-402. [10.1002/jmv.25678](https://doi.org/10.1002/jmv.25678)
2. Coronavirus Disease (COVID-19). (2020). <https://www.who.int/emergencies/diseases/novel-coronavirus-2019>.
3. Bartsch SM, Ferguson MC, McKinnell JA, O'Shea KJ, Wedlock PT, Siegmund SS, Lee BY: The potential health care costs and resource use associated with COVID-19 in the United States. *Health Aff*. 2020, 39:927-935. [10.1377/hlthaff.2020.00426](https://doi.org/10.1377/hlthaff.2020.00426)
4. World Health Organization: Severe falciparum malaria. *Trans R Soc Trop Med Hyg*. 2000, 94:1-90.
5. Genton B, D'Acremont V: Clinical features of malaria in returning travelers and migrants. *Travelers' Malaria*. Schlagenhauf-Lawlor P (ed): BC Decker, Hamilton; 2001. 371-392.
6. White NJ: The treatment of malaria. *N Engl J Med*. 1996, 335:800-806. [10.1056/NEJM199609123351107](https://doi.org/10.1056/NEJM199609123351107)
7. Zoller T, Junghanss T, Kapaun A, et al.: Intravenous artesunate for severe malaria in travelers. *Emerg Infect Dis*. 2011, 17:771-777. [10.3201/eid1705.101229](https://doi.org/10.3201/eid1705.101229)
8. Yamin M: Counting the cost of COVID-19. *Int J Inf Technol Decis Mak*. 2020, 12:311-317. [10.1007/s41870-020-00466-0](https://doi.org/10.1007/s41870-020-00466-0)
9. Nicola M, Alsafi Z, Sohrabi C, et al.: The socio-economic implications of the coronavirus pandemic (COVID-19): a review. *Int J Surg*. 2020, 78:185-193. [10.1016/j.ijsu.2020.04.018](https://doi.org/10.1016/j.ijsu.2020.04.018)
10. Amimo F, Lambert B, Magit A: What does the COVID-19 pandemic mean for HIV, tuberculosis, and malaria control?. *Trop Med Health*. 2020, 48:32. [10.1186/s41182-020-00219-6](https://doi.org/10.1186/s41182-020-00219-6)
11. Jackson SL, Tong X, King RJ, Loustalot F, Hong Y, Ritchey MD: National burden of heart failure events in the United States, 2006 to 2014. *Circulation: Heart Failure*. 2018, 11:[www.ahajournals.org/doi/epub/10.1161/CIRCHEARTFAILURE.117.004873](https://doi.org/10.1161/CIRCHEARTFAILURE.117.004873)